COMPANY PROFILE // THE 014 REPORT
Aquestive Therapeutics, Inc.
AQST (Nasdaq) · Formerly: MonoSol Rx, Inc.
Assembled from 2 government sources in 0.3 s
FLAGS · DISCLOSURE · SUMMARY
Missing or hidden
No flag from the records checked. 25 of 26 lists and sources checked came back clear (panel below).
✓ SEC filings✓ SAM registrationpossible match✓ State registrationpossible match✓ Lobbying registrationpossible match✗ LEI✗ IRS return✗ Website
No LEI, no IRS return, no website on record.
Aquestive Therapeutics, Inc. is an SEC-registered operating company in pharmaceutical preparations, incorporated in DE, based in Warren, NJ; listed as AQST (Nasdaq).[source] It reported revenue of $44.5 million for the fiscal year ended 2025-12-31.[source] It has filed 94 documents with the SEC in the last 12 months; the latest is Form 4, filed 2026-11-16.[source] 2 lobbying disclosure filings name a client with this company's exact name (possible match).[source] Its largest institutional holders on 13F filings are Bratton Capital Management, L.P., BlackRock, Inc., RTW INVESTMENTS, LP (as of 2026-06-30).[source] 25 of 26 lists and sources checked came back clear; the rest are listed with their result.[source]
- red0
- amber0
- info0
- Bratton Capital Management, L.P.$40.8M
- BlackRock, Inc.$33.6M
- RTW INVESTMENTS, LP$30.9M
- VANGUARD CAPITAL MANAGEMENT LLC$19.1M
- FEDERATED HERMES, INC.$12.9M
- STATE STREET CORP$12.2M
- GEODE CAPITAL MANAGEMENT, LLC$10.9M
- SAMSARA BIOCAPITAL, LLC$10.4M
RECORD · WEB
Ask about this entity
Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).
PEOPLE · COUNSEL · LINKS
Leadership, advisers and links
Officers and directors (Forms 3, 4, 5)
- BRAENDER LORI J · Chief Legal Officer (Officer) · latest Form 4 2026-03-11 · filing · LinkedIn search
- Barber Daniel · President and CEO (Officer) · latest Form 4 2026-03-11 · filing · LinkedIn search
- Boyd Peter E. · Chief People Officer (Officer) · latest Form 4 2026-03-11 · filing · LinkedIn search
- Cioffi Melina · SVP, Regulatory Affairs (Officer) · latest Form 4 2026-03-11 · filing · LinkedIn search
- Davis Matthew W. · Chief Development Officer (Officer) · latest Form 4 2026-03-11 · filing · LinkedIn search
- Greenhawt Matthew J. · Chief Medical Officer (Officer) · latest Form 4 2026-03-11 · filing · LinkedIn search
- Jung Cassie · Chief Operating Officer (Officer) · latest Form 4 2026-03-11 · filing · LinkedIn search
- Korczynski Sherry · Chief Commercial Officer (Officer) · latest Form 4 2026-03-11 · filing · LinkedIn search
- Kraus Carl N · Chief Medical Officer (Officer) · latest Form 4 2025-10-17 · filing · LinkedIn search
- TOTH A ERNEST JR · Chief Financial Officer (Officer) · latest Form 4 2026-03-11 · filing · LinkedIn search
- BROWN GREGORY B · Director · latest Form 4 2025-06-12 · filing · LinkedIn search
- Cochran John · Director · latest Form 4 2025-06-12 · filing · LinkedIn search
As reported to the SEC by the insiders themselves; SEC insider transactions data sets (Forms 3, 4, 5): 2026q1, 2025q4, 2025q3, 2025q2.
Legal counsel, as publicly named
- Dechert LLP · Exhibit 5.1 legal opinion, S-3 filed 2026-06-26
EVERY LIST AND SOURCE · DATED
Checked and clear
26 lists and sources checked: 25 CLEAR, 1 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.
EVERY IDENTIFIER · LINKED
ID crosswalk
| Identifier | Value | Record |
|---|---|---|
| SEC CIK | 0001398733 | source |
| UEIpossible match | XBKKRRJPR255 | source |
| CAGEpossible match | 5MZL2 | source |
| EIN | 20-8623253 | source |
| NY DOS ID | 7601983 | record |
| LDA clientpossible match | 212115 | record |
| LDA clientpossible match | 145783 | record |
| Business address (SEC) | 184 LIBERTY CORNER ROAD, SUITE 305, WARREN, NJ | source |
Does not exist in the records we hold: LEI, FDIC certificate.
EACH FEEDS WATCH
Dates coming up
- 2027-03-31 · in 129 days · Next 10-K due (period ended 2026-12-31; Non-accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
- 2027-05-15 · in 174 days · Next 10-Q due (period ended 2027-03-31; Non-accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
- 2027-10-14 · in 326 days · SAM registration expires (UEI XBKKRRJPR255)possible match
PEERS BY SIC CODE
Industry context
SIC 2834 (pharmaceutical preparations): 568 companies in our records share this code.
federal dollars
lobbying filings
SEC filings in 12 months
flags
Peers, each with its 014
- PFIZER INC · 124 SEC filings in 12 months · $25.74B federal (possible match)
- Merck & Co., Inc. · 150 SEC filings in 12 months · $13.51B federal (possible match)
- ABBOTT LABORATORIES · 118 SEC filings in 12 months · 1 flag · $2.64B federal (possible match)
- ASTRAZENECA PLC · 140 SEC filings in 12 months · $602.8M federal (possible match)
- TEVA PHARMACEUTICAL INDUSTRIES LTD · 168 SEC filings in 12 months · $77.6M federal (possible match)
- NOVARTIS AG · 34 SEC filings in 12 months · $41.9M federal (possible match)
- Spero Therapeutics, Inc. · 41 SEC filings in 12 months · 4 flags · $39.5M federal (possible match)
- Grifols SA · 18 SEC filings in 12 months · $22.5M federal (possible match)
- SCYNEXIS INC · 54 SEC filings in 12 months · 3 flags · $18.5M federal (possible match)
- Ensysce Biosciences, Inc. · 45 SEC filings in 12 months · 3 flags · $15.1M federal (possible match)
- UNITED THERAPEUTICS Corp · 454 SEC filings in 12 months · 2 flags · $6.8M federal (possible match)
- Zoetis Inc. · 144 SEC filings in 12 months · 1 flag · $6.7M federal (possible match)
SHARED PEOPLE · SHARED ADDRESS
Network neighbours
Shared directors and officers
- CATALYST PHARMACEUTICALS, INC. · Daly Richard J
- Crestline Lending Solutions, LLC · Cochran John
- DiaMedica Therapeutics Inc. · Krop Julie
- LISATA THERAPEUTICS, INC. · BROWN GREGORY B
EVERY SOURCE · NEWEST FIRST
One timeline
- 2027-10-14 registration SAM registration expiry (UEI XBKKRRJPR255) · SAM.gov
- 2026-11-16 filing 8-K items 7.01,9.01 · SEC EDGAR
- 2026-11-12 filing 144 · SEC EDGAR
- 2026-11-05 filing 8-K items 7.01,9.01 · SEC EDGAR
- 2026-11-03 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-11-03 filing 8-K items 2.02,7.01,9.01 · SEC EDGAR
- 2026-10-19 filing 8-K items 5.03,9.01 · SEC EDGAR
- 2026-10-15 filing 8-K items 7.01,9.01 · SEC EDGAR
- 2026-10-14 filing 8-K items 1.01,9.01 · SEC EDGAR
- 2026-09-29 officer change 8-K items 5.02,9.01 · SEC EDGAR
- 2026-09-25 filing 8-K items 7.01,9.01 · SEC EDGAR
- 2026-09-17 filing 8-K items 7.01,8.01,9.01 · SEC EDGAR
- 2026-09-15 filing 144 · SEC EDGAR
- 2026-09-09 filing 144 · SEC EDGAR
- 2026-08-17 filing 144 · SEC EDGAR
- 2026-08-11 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-08-11 filing 8-K items 2.02,7.01,9.01 · SEC EDGAR
- 2026-08-10 filing 8-K items 7.01,8.01,9.01 · SEC EDGAR
- 2026-07-15 filing 144 · SEC EDGAR
- 2026-07-09 filing 424B3 · SEC EDGAR
- 2026-07-08 filing EFFECT · SEC EDGAR
- 2026-06-26 filing S-3 · SEC EDGAR
- 2026-06-23 filing 144 · SEC EDGAR
- 2026-06-15 filing 144 · SEC EDGAR
- 2026-06-10 filing 8-K items 5.07,9.01 · SEC EDGAR
- 2026-05-15 filing 144 · SEC EDGAR
- 2026-05-13 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-05-13 filing 8-K items 1.01,1.02,2.02,2.03,3.02,7.01,9.01 · SEC EDGAR
- 2026-04-24 filing ARS · SEC EDGAR
- 2026-04-24 filing DEFA14A · SEC EDGAR
170 earlier entries
- 2026-04-24 filing Proxy statement
- 2026-03-30 filing 8-K items 7.01,9.01
- 2026-03-20 officer change 8-K items 5.02,7.01,9.01
- 2026-03-11 insider First Form 3/4/5 on record for BRAENDER LORI J (Chief Legal Officer)
- 2026-03-11 insider First Form 3/4/5 on record for Greenhawt Matthew J. (Chief Medical Officer)
- 2026-03-11 insider First Form 3/4/5 on record for TOTH A ERNEST JR (Chief Financial Officer)
- 2026-03-04 filing S-8
- 2026-03-04 filing Annual report (10-K)
- 2026-03-04 filing 8-K items 1.01,2.02,3.02,7.01,9.01
- 2026-02-26 filing 8-K items 7.01,9.01
- 2026-02-02 filing 8-K items 7.01,9.01
- 2026-01-21 filing S-8
- 2026-01-09 filing 8-K items 8.01,9.01
- 2025-11-17 filing 144
- 2025-11-12 insider First Form 3/4/5 on record for Davis Matthew W. (Chief Development Officer)
- 2025-11-06 filing 8-K items 7.01,9.01
- 2025-11-05 filing Quarterly report (10-Q)
- 2025-11-05 filing 8-K items 2.02,7.01,9.01
- 2025-10-15 filing 144
- 2025-10-15 filing 144
- 2025-10-15 filing 144
- 2025-10-08 filing 8-K items 8.01,9.01
- 2025-10-01 filing 8-K items 7.01,9.01
- 2025-09-29 filing 144
- 2025-09-26 filing 144
- 2025-09-22 insider First Form 3/4/5 on record for Barber Daniel (President and CEO)
- 2025-09-19 filing 144
- 2025-09-08 filing 8-K items 7.01,9.01
- 2025-09-08 insider First Form 3/4/5 on record for Boyd Peter E. (Chief People Officer)
- 2025-09-08 insider First Form 3/4/5 on record for Jung Cassie (Chief Operating Officer)
- 2025-09-05 filing 144
- 2025-09-04 filing 144
- 2025-09-04 filing 8-K items 7.01,9.01
- 2025-08-15 filing 8-K items 1.01,7.01,9.01
- 2025-08-14 filing 424B5
- 2025-08-14 filing 8-K items 1.01,7.01,9.01
- 2025-08-12 insider First Form 3/4/5 on record for Kraus Carl N (Chief Medical Officer)
- 2025-08-11 filing Quarterly report (10-Q)
- 2025-08-11 filing 8-K items 2.02,7.01,9.01
- 2025-07-15 filing 8-K items 8.01,9.01
- 2025-06-16 filing 8-K items 7.01,9.01
- 2025-06-12 insider First Form 3/4/5 on record for BROWN GREGORY B (Director)
- 2025-06-12 insider First Form 3/4/5 on record for Cochran John (Director)
- 2025-06-12 insider First Form 3/4/5 on record for Jenkins Abigail L. (Director)
- 2025-06-12 insider First Form 3/4/5 on record for Krop Julie (Director)
- 2025-06-12 insider First Form 3/4/5 on record for MORRIS TIMOTHY E (Director)
- 2025-06-12 insider First Form 3/4/5 on record for Taglietti Marco (Director)
- 2025-06-11 filing 8-K items 5.07
- 2025-06-10 insider First Form 3/4/5 on record for Korczynski Sherry (Chief Commercial Officer)
- 2025-06-02 filing 8-K items 7.01,9.01
- 2025-05-12 filing Quarterly report (10-Q)
- 2025-05-12 filing 8-K items 2.02,7.01,9.01
- 2025-05-07 insider First Form 3/4/5 on record for Cioffi Melina (SVP, Regulatory Affairs)
- 2025-04-25 filing ARS
- 2025-04-25 filing DEFA14A
- 2025-04-25 filing Proxy statement
- 2025-04-01 filing 8-K items 7.01,9.01
- 2025-03-10 filing 8-K items 7.01,9.01
- 2025-03-05 filing Annual report (10-K)
- 2025-03-05 filing 8-K items 2.02,7.01,9.01
- 2025-02-12 filing 8-K items 8.01,9.01
- 2025-01-24 filing S-8
- 2025-01-13 filing 8-K items 2.02,7.01,9.01
- 2024-12-19 filing 8-K items 8.01,9.01
- 2024-12-02 filing 8-K items 7.01,8.01,9.01
- 2024-11-07 officer change 8-K items 5.02
- 2024-11-06 filing 8-K items 7.01,9.01
- 2024-11-04 filing Quarterly report (10-Q)
- 2024-11-04 filing 8-K items 2.02,7.01,9.01
- 2024-10-25 filing 8-K items 8.01,9.01
- 2024-10-24 filing 8-K items 7.01,8.01,9.01
- 2024-10-16 filing 8-K items 5.03,9.01
- 2024-09-27 filing 8-K items 7.01,8.01,9.01
- 2024-09-09 filing 8-K items 7.01,9.01
- 2024-08-14 filing 8-K items 8.01,9.01
- 2024-08-06 filing Quarterly report (10-Q)
- 2024-08-06 filing 8-K items 2.02,7.01,9.01
- 2024-07-25 filing 8-K items 7.01,8.01,9.01
- 2024-06-21 filing 8-K items 5.07
- 2024-06-12 filing 3/A
- 2024-06-07 filing 8-K items 7.01
- 2024-06-06 officer change 8-K items 5.02
- 2024-05-08 filing 8-K items 7.01
- 2024-05-07 filing Quarterly report (10-Q)
- 2024-05-07 filing 8-K items 2.02,7.01,9.01
- 2024-04-29 filing 8-K items 8.01,9.01
- 2024-04-26 filing ARS
- 2024-04-26 filing DEFA14A
- 2024-04-26 filing Proxy statement
- 2024-04-24 filing 424B2
- 2024-04-24 filing 424B2
- 2024-04-23 filing EFFECT
- 2024-04-22 filing 8-K items 8.01
- 2024-04-19 filing CORRESP
- 2024-04-19 filing CORRESP
- 2024-04-16 filing CORRESP
- 2024-04-08 filing UPLOAD
- 2024-04-03 filing S-3
- 2024-04-01 officer change 8-K items 5.02
- 2024-03-21 filing 8-K items 1.01,8.01,9.01
- 2024-03-21 filing 424B5
- 2024-03-19 filing 424B5
- 2024-03-15 filing 144
- 2024-03-15 filing 8-K items 8.01
- 2024-03-08 filing 144
- 2024-03-05 filing Annual report (10-K)
- 2024-03-05 filing 8-K items 2.02,7.01
- 2024-02-12 filing S-8
- 2023-12-19 filing UPLOAD
- 2023-12-13 filing CORRESP
- 2023-12-08 filing 8-K items 7.01
- 2023-12-05 filing 8-K items 8.01
- 2023-11-08 filing 8-K items 7.01
- 2023-11-06 filing Quarterly report (10-Q)
- 2023-11-06 filing 8-K items 2.02,7.01
- 2023-11-02 filing 8-K items 1.01,1.02,2.03,3.02,8.01,9.01
- 2023-10-27 filing UPLOAD
- 2023-10-10 filing 8-K items 8.01
- 2023-10-02 filing 424B3
- 2023-09-29 filing EFFECT
- 2023-09-27 filing CORRESP
- 2023-09-25 filing UPLOAD
- 2023-09-21 filing S-3
- 2023-09-20 filing 8-K items 8.01
- 2023-08-11 filing 8-K items 7.01
- 2023-08-09 filing S-8
- 2023-08-07 filing 8-K items 2.02,7.01,9.01
- 2023-08-07 filing Quarterly report (10-Q)
- 2023-08-02 filing 8-K items 1.01
- 2023-07-27 filing 8-K items 7.01
- 2023-06-29 filing 8-K items 7.01,8.01,9.01
- 2023-06-23 filing 8-K items 5.07
- 2023-05-31 filing 8-K items 7.01,8.01,9.01
- 2023-05-02 filing Quarterly report (10-Q)
- 2023-05-02 filing 8-K items 2.02,7.01,9.01
- 2023-05-02 filing ARS
- 2023-04-28 filing DEFA14A
- 2023-04-28 filing Proxy statement
- 2023-04-18 filing PRE 14A
- 2023-04-13 filing 8-K items 8.01
- 2023-03-31 filing Annual report (10-K)
- 2023-03-13 filing 8-K items 7.01
- 2023-03-07 filing 8-K items 7.01,9.01
- 2023-03-07 filing 8-K items 2.02,7.01,9.01
- 2023-03-06 filing 8-K items 1.01
- 2023-02-07 filing 8-K items 5.03,9.01
- 2023-01-24 filing 8-K items 8.01,9.01
- 2023-01-18 filing S-8
- 2023-01-03 filing 8-K items 3.01
- 2022-12-22 filing 8-K items 8.01,9.01
- 2022-12-20 filing 8-K items 8.01
- 2022-11-07 filing 8-K items 8.01
- 2022-11-02 filing 8-K items 7.01,9.01
- 2022-11-01 filing Quarterly report (10-Q)
- 2022-11-01 filing 8-K items 2.02,9.01
- 2022-10-27 filing 8-K items 1.01,8.01,9.01
- 2022-10-24 filing 8-K items 8.01,9.01
- 2022-10-11 filing 8-K items 8.01,9.01
- 2022-09-28 filing 8-K items 1.01,8.01,9.01
- 2022-09-27 filing 8-K items 7.01,8.01,9.01
- 2022-09-13 filing 8-K items 7.01,8.01,9.01
- 2022-09-07 filing 8-K items 8.01,9.01
- 2022-09-07 filing 424B5
- 2022-08-31 filing 8-K items 8.01,9.01
- 2022-08-24 filing 8-K items 8.01
- 2022-08-10 officer change 8-K items 3.02,5.02,8.01,9.01
- 2022-08-03 filing 8-K items 7.01,9.01
- 2022-08-02 filing 8-K items 2.02,9.01
- 2022-08-02 filing Quarterly report (10-Q)
- 2022-07-19 officer change 8-K items 5.02
RENDERED FROM THIS PAGE
Relationship graph
Holders from 13F filings, subsidiaries from the GLEIF tree (by LEI), lobbying firms from LDA (possible match), agencies from USAspending, people from Forms 3/4/5, counsel from Exhibit 5.1, shared boards from Forms 3/4/5.
DATA MOTION // NEWEST FIRSTWhat changed
- 2026-11-16 (within 7 days) 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-11-05 (within 30 days) 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-11-03 (within 30 days) 10-Q filed
- 2026-11-03 (within 30 days) 8-K filed: Item 2.02 results of operations; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-10-19 (older) 8-K filed: Item 5.03 charter or bylaw amendment; Item 9.01 exhibits
- 2026-10-15 (older) 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-10-14 (older) 8-K filed: Item 1.01 material agreement; Item 9.01 exhibits
- 2026-09-29 (older) 8-K filed: Item 5.02 officer or director change; Item 9.01 exhibits
Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-22; the colour is also written out in words.
COUNTS FROM THIS PAGERelationships at a glance
PRICE · FILINGS · POSTS · NEWSMarket & news
- Price
- NASDAQ:AQST The chart widget (TradingView) shows the price and the previous session's close. Seraphix publishes no price of its own.
- Open in
Open in…
Price and chart
News
Analyst estimates and earnings
Institutional holders
Short interest
Official social
Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
- Financials
- Filed figures: published SEC values, each linked to its filing.
- Official posts
- Links to posts from the company's and agencies' verified accounts: not connected yet.
- News
- Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER1. Identity
12 possible matches held apart, matched by name only, not counted above; 1 record under a former name, shown apart.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| SEC CIK | 1398733 | id:sec-anchor: the SEC registrant record of this company | SEC EDGAR |
| Ticker / exchange | AQST / Nasdaq | SEC company record: ticker and exchange as listed on the SEC company record | SEC EDGAR |
| EIN | 208623253 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001398733 | SEC EDGAR / IRS |
| CUSIP | 03843E104 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001398733 | SEC EDGAR |
possible match: matched by name only, not merged (5)
Identifiers carried by records that share the company's exact name. Not merged into the identity above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| LDA client id | 212115 (AQUESTIVE THERAPEUTICS, INC (lobbying via RUBICON ADVISORS, LLC)) | name-exact:legal-name: same registered legal name as 'Aquestive Therapeutics, Inc.' | Lobbying Disclosure Act (LDA) |
| LDA client id | 145783 (AQUESTIVE THERAPEUTICS, INC. (lobbying via STEPTOE LLP)) | name-exact:legal-name: same registered legal name as 'Aquestive Therapeutics, Inc.' | Lobbying Disclosure Act (LDA) |
| EPA FRS id | 110003138444 (AQUESTIVE THERAPEUTICS) | name-exact: exact name match to 'Aquestive Therapeutics, Inc.' (no other entity shares the name) | EPA ECHO facilities |
| EPA FRS id | 110072337812 (AQUESTIVE THERAPEUTICS INC) | name-exact:legal-name: same registered legal name as 'Aquestive Therapeutics, Inc.' | EPA ECHO facilities |
| EPA FRS id | 110040276652 (AQUESTIVE THERAPEUTICS INC.) | name-exact:legal-name: same registered legal name as 'Aquestive Therapeutics, Inc.' | EPA ECHO facilities |
former name (shown apart, not merged) (1)
- former nameMonoSol Rx · ClinicalTrials.gov
AS FILED · EACH WITH ITS DATE AND FILING2. Filed figures
Key figures (annual filing)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Revenue (fiscal year ended 2025-12-31) | $44,545,000 | 2025-12-31 | 10-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax | as filed | 2026-11-22 09:22 UTC | Report an error |
| Net income (loss) (fiscal year ended 2025-12-31) | -$83,784,000 | 2025-12-31 | 10-K, XBRL NetIncomeLoss | as filed | 2026-11-22 09:22 UTC | Report an error |
| Total assets (at 2025-12-31) | $160,425,000 | 2025-12-31 | 10-K, XBRL Assets | as filed | 2026-11-22 09:22 UTC | Report an error |
| Stockholders' equity (at 2025-12-31) | -$33,662,000 | 2025-12-31 | 10-K, XBRL StockholdersEquity | as filed | 2026-11-22 09:22 UTC | Report an error |
| Cash and cash equivalents (at 2025-12-31) | $121,169,000 | 2025-12-31 | 10-K, XBRL CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents | as filed | 2026-11-22 09:22 UTC | Report an error |
Company profile facts (SEC)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| SEC entity type | operating | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-22 09:22 UTC | Report an error |
| SIC industry | 2834 Pharmaceutical Preparations | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-22 09:22 UTC | Report an error |
| State of incorporation | DE | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-22 09:22 UTC | Report an error |
| Fiscal year end (MMDD) | 1231 | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-22 09:22 UTC | Report an error |
| Business address | 184 LIBERTY CORNER ROAD, SUITE 305, WARREN, NJ | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-22 09:22 UTC | Report an error |
| Exchanges | Nasdaq | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-22 09:22 UTC | Report an error |
Other filed values
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Operating cash flow (fiscal year ended 2025-12-31) | -$52,432,000 | 2025-12-31 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | as filed | 2026-11-22 09:22 UTC | Report an error |
| Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31) | $562,000 | 2025-12-31 | 10-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment | as filed | 2026-11-22 09:22 UTC | Report an error |
| Long-term debt (at 2025-12-31) | $45,000,000 | 2025-12-31 | 10-K, XBRL LongTermDebt | as filed | 2026-11-22 09:22 UTC | Report an error |
| Operating lease liabilities (at 2025-12-31) | $4,968,000 | 2025-12-31 | 10-K, XBRL OperatingLeaseLiability | as filed | 2026-11-22 09:22 UTC | Report an error |
| Form D total offering amount (D filed 2018-05-09) | $9,063,956 | 2018-05-09 | D | as filed | 2026-11-22 09:22 UTC | Report an error |
| Form D total amount sold (D filed 2018-05-09) | $9,063,956 | 2018-05-09 | D | as filed | 2026-11-22 09:22 UTC | Report an error |
| Form D industry group | Pharmaceuticals | 2018-05-09 | D | as filed | 2026-11-22 09:22 UTC | Report an error |
| Form D revenue range | Decline to Disclose | 2018-05-09 | D | as filed | 2026-11-22 09:22 UTC | Report an error |
| Form D date of first sale | 2018-04-24 | 2018-05-09 | D | as filed | 2026-11-22 09:22 UTC | Report an error |
Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-03 · accession 0001398733-26-000074
| Item | Value | Period | Form | Filed | Accession | Retrieved | Report |
|---|---|---|---|---|---|---|---|
| Revenue | $7,557,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-03 | 0001398733-26-000074 | 2026-11-22 09:22 UTC | Report an error |
| Net income (loss) | -$16,496,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-03 | 0001398733-26-000074 | 2026-11-22 09:22 UTC | Report an error |
| Interest expense | $1,845,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-03 | 0001398733-26-000074 | 2026-11-22 09:22 UTC | Report an error |
| Cash and cash equivalents | $90,349,000 | at 2026-09-30 | 10-Q | 2026-11-03 | 0001398733-26-000074 | 2026-11-22 09:22 UTC | Report an error |
| Contract liabilities (total) | $19,665,000 | at 2026-09-30 | 10-Q | 2026-11-03 | 0001398733-26-000074 | 2026-11-22 09:22 UTC | Report an error |
| Contract liabilities, current | $1,092,000 | at 2026-09-30 | 10-Q | 2026-11-03 | 0001398733-26-000074 | 2026-11-22 09:22 UTC | Report an error |
| Contract liabilities, noncurrent | $18,573,000 | at 2026-09-30 | 10-Q | 2026-11-03 | 0001398733-26-000074 | 2026-11-22 09:22 UTC | Report an error |
| Debt due in year 5 | $55,000,000 | at 2026-09-30 | 10-Q | 2026-11-03 | 0001398733-26-000074 | 2026-11-22 09:22 UTC | Report an error |
Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.
No estimates: every value is as filed and links to the filing it came from.
Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.
NEWEST FIRST · EACH LINKS TO ITS FILING3. Registration and filing timeline
- 2026-11-16 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-11-05 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-11-03 Filing 10-Q filed
- 2026-11-03 Filing 8-K filed: Item 2.02 results of operations; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-10-19 Filing 8-K filed: Item 5.03 charter or bylaw amendment; Item 9.01 exhibits
- 2026-10-15 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-10-14 Filing 8-K filed: Item 1.01 material agreement; Item 9.01 exhibits
- 2026-09-29 Filing 8-K filed: Item 5.02 officer or director change; Item 9.01 exhibits
- 2026-09-25 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-09-17 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-08-11 Filing 10-Q filed
- 2026-08-11 Filing 8-K filed: Item 2.02 results of operations; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-08-10 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-07-09 Filing 424B3 filed
- 2026-07-08 Filing EFFECT filed
- 2026-06-26 Filing S-3 filed
- 2026-06-10 Filing 8-K filed: Item 5.07 shareholder vote; Item 9.01 exhibits
- 2026-05-13 Filing 10-Q filed
- 2026-05-13 Filing 8-K filed: Item 1.01 material agreement; Item 1.02 agreement terminated; Item 2.02 results of operations; Item 2.03 new financial obligation; Item 3.02 unregistered equity sale; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-04-24 Filing ARS filed
- 2026-04-24 Filing DEFA14A filed
- 2026-04-24 Filing DEF 14A filed
- 2026-03-30 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-03-20 Filing 8-K filed: Item 5.02 officer or director change; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-03-04 Filing S-8 filed
8-K item text, as filed (excerpts)
- 2026-11-16 8-K Item 7.01
Regulation FD Disclosure. Aquestive Therapeutics, Inc. (the "Company") is furnishing this Current Report on Form 8-K in connection with the disclosure of information, in the form of an investor presentation, to be given at meetings with institutional investors, analysts and others. This information may be amended or updated at any time and from time to time through another Current Report on Form 8-K, a later Company filing or other means. A copy of the Company's investor presentation given to investors, analysts and others at the Jefferies Global Healthcare Conference on November 16, 2026 is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated into this Item… the 8-K · retrieved 2026-11-22 09:22 UTC - 2026-11-05 8-K Item 7.01
Regulation FD Disclosure. Aquestive Therapeutics, Inc. (the "Company") is furnishing this Current Report on Form 8-K in connection with the disclosure of information, in the form of an investor presentation, to be given at meetings with institutional investors, analysts and others. This information may be amended or updated at any time and from time to time through another Current Report on Form 8-K, a later Company filing or other means. A copy of the Company’s investor presentation is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference. The investor presentation is available on the Events and Presentations Page of the… the 8-K · retrieved 2026-11-22 09:22 UTC - 2026-11-03 8-K Item 2.02
Results of Operations and Financial Condition. On November 3, 2026, Aquestive Therapeutics, Inc. (the “Company”) issued a press release announcing its reported financial results for the third quarter ended September 30, 2026 and provided an update on recent developments in its business. A copy of the Company’s press release and the attached financial schedules are attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated in this Item 2.02 by reference. The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of, or otherwise subject to the liabilities of Section 18 of the Exchange Act,nor shall it be deemed to be… the 8-K · retrieved 2026-11-22 09:22 UTC - 2026-11-03 8-K Item 7.01
Regulation FD Disclosure. The Company is furnishing this Current Report on Form 8-K in connection with the disclosure of information, in the form of an investor presentation, to be given at meetings with institutional investors, analysts and others. This information may be amended or updated at any time and from time to time through another Current Report on Form 8-K, a later Company filing or other means. A copy of the Company’s investor presentation is attached hereto as Exhibit 99.2 to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference. The investor presentation is available on the Events and Presentations page in the Investors section of the Company’s… the 8-K · retrieved 2026-11-22 09:22 UTC - 2026-10-19 8-K Item 5.03
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On October 15, 2026, the Board of Directors (the “Board”) of Aquestive Therapeutics, Inc. (the “Company”), in connection with its periodic review of corporate governance matters, approved and adopted amended and restated bylaws (the "Amended Bylaws"), effective October 15, 2026. The Amended Bylaws supersede the previously existing Amended and Restated Bylaws of the Company (the "Prior Bylaws"). Specifically, Article I, Section 11 of the Prior Bylaws, which sets forth requirements for stockholder nominations of candidates for election to the Board, has been amended to eliminate the requirement that the proposing… the 8-K · retrieved 2026-11-22 09:22 UTC
Each excerpt is the first part of the item's own text, copied as filed and cut at a word; the filing has the rest.
POSSIBLE MATCHES · NAME ONLY6. Lobbying (LDA)
2 lobbying records carry this company's exact name, hiring 2 lobbying firms. These are possible matches until the accuracy score, so they are not counted in the headline.
possible match: matched by name only, not merged (2)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchAQUESTIVE THERAPEUTICS, INC (lobbying via RUBICON ADVISORS, LLC) · exact legal name · sx:lda:212115 Compare
- possible matchAQUESTIVE THERAPEUTICS, INC. (lobbying via STEPTOE LLP) · exact legal name · sx:lda:145783 Compare
POSSIBLE MATCHES · GROUPED BY SOURCE8. Enforcement by agency
EPA ECHO facilities (3)
possible match: matched by name only, not merged (3)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchAQUESTIVE THERAPEUTICS · exact name match to 'Aquestive Therapeutics, Inc.' (no other entity shares the name) · sx:epa:110003138444 Compare
- possible matchAQUESTIVE THERAPEUTICS INC · exact legal name · sx:epa:110072337812 Compare
- possible matchAQUESTIVE THERAPEUTICS INC. · exact legal name · sx:epa:110040276652 Compare
Each record's own page holds its date and the agency document. Matched by exact name only; none of these is counted in the headline.
AS FILED · LARGEST HOLDERS10. 13F institutional holders
| Rank | Holder (13F filer) | Value held | As of | Source | Retrieved | Report |
|---|---|---|---|---|---|---|
| 1 | Bratton Capital Management, L.P. | $40,813,585 | 2026-06-30 | SEC 13F filing | 2026-11-22 09:22 UTC | Report an error |
| 2 | BlackRock, Inc. | $33,568,590 | 2026-06-30 | SEC 13F filing | 2026-11-22 09:22 UTC | Report an error |
| 3 | RTW INVESTMENTS, LP | $30,894,119 | 2026-06-30 | SEC 13F filing | 2026-11-22 09:22 UTC | Report an error |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | $19,071,657 | 2026-06-30 | SEC 13F filing | 2026-11-22 09:22 UTC | Report an error |
| 5 | FEDERATED HERMES, INC. | $12,948,253 | 2026-06-30 | SEC 13F filing | 2026-11-22 09:22 UTC | Report an error |
| 6 | STATE STREET CORP | $12,180,563 | 2026-06-30 | SEC 13F filing | 2026-11-22 09:22 UTC | Report an error |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | $10,913,743 | 2026-06-30 | SEC 13F filing | 2026-11-22 09:22 UTC | Report an error |
| 8 | SAMSARA BIOCAPITAL, LLC | $10,400,000 | 2026-06-30 | SEC 13F filing | 2026-11-22 09:22 UTC | Report an error |
| 9 | BANK OF AMERICA CORP /DE/ | $6,940,640 | 2026-06-30 | SEC 13F filing | 2026-11-22 09:22 UTC | Report an error |
| 10 | Sio Capital Management, LLC | $6,182,488 | 2026-06-30 | SEC 13F filing | 2026-11-22 09:22 UTC | Report an error |
13F as filed: the holder's own report of its position value at the quarter end.
POSSIBLE MATCHES · LICENCES, PERMITS, CITY AND STATE RECORDS13. Permits and local records
7 state and city records carry this company's exact name, from 4 sources. Possible matches only.
State licences (4)
possible match: matched by name only, not merged (4)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchAQUESTIVE THERAPEUTICS, INC. · exact legal name · sx:elic:ctcred:2481993 Compare
- possible matchAquestive Therapeutics · exact name match to 'Aquestive Therapeutics, Inc.' (no other entity shares the name) · sx:elic:ctcred:2662568 Compare
- possible matchAquestive Therapeutics, Inc. · exact legal name · sx:elic:ctcred:2482035 Compare
- possible matchAquestive Therapeutics, Inc. · exact legal name · sx:elic:ctcred:1528437 Compare
ClinicalTrials.gov (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchAquestive Therapeutics · exact name match to 'Aquestive Therapeutics, Inc.' (no other entity shares the name) · sx:ctgov:hb23086b337d5c500 Compare
New York corporations (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchAQUESTIVE THERAPEUTICS, INC. · exact legal name · sx:nydos:7601983 Compare
USAspending (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchAQUESTIVE THERAPEUTICS, INC. · exact legal name · sx:usaspending:XBKKRRJPR255 Compare
WHAT THIS PAGE READ
Sources
JSON · MCP · API
API and agents
The same profile as JSON: GET /company/1398733.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0001398733. Every source URL used is listed in the file.
Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.